Quarterly ResultApr 30, 2026, 04:24 PM
KIDS Q1 Revenue +13% to $59.4M; Adj EBITDA $2.2M; Raises 2026 Guidance
AI Summary
OrthoPediatrics Corp. reported a strong first quarter for 2026, with total revenue increasing 13% year-over-year to $59.4 million. The company achieved adjusted EBITDA of $2.2 million, a significant improvement from a loss in the prior year, and reduced free cash flow usage by 40%. This performance was driven by robust domestic and international growth across its Trauma & Deformity and Scoliosis segments, leading the company to increase its full-year 2026 revenue guidance.
Key Highlights
- Q1 2026 total revenue increased 13% to $59.4 million, up from $52.4 million in Q1 2025.
- Q1 2026 adjusted EBITDA was $2.2 million, compared to a loss of $0.4 million in Q1 2025.
- Q1 2026 net loss was $10.7 million, consistent with $10.7 million in Q1 2025.
- Q1 2026 free cash flow usage reduced by 40% to $5.0 million, from $8.4 million in Q1 2025.
- Full-year 2026 revenue guidance increased to $263.0 million-$267.0 million, up from $262.0 million-$266.0 million.
- Domestic revenue grew 11% to $45.3 million, and international revenue grew 22% to $14.1 million.
- Trauma & Deformity revenue increased 14% to $43.0 million, and Scoliosis revenue increased 13% to $15.4 million.